SCHEMBL1018931

SCHEMBL1018931

Cc1cnccc1-c1cccc(C(=O)O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.60
AKR1C3 P42330 1/20 0.53
AKR1C2 P52895 1/20 0.53
NR1H4 Q96RI1 2/20 0.51
CCNC P24863 1/20 0.51
CDK8 P49336 1/20 0.51
DDT P30046 1/20 0.50
PTGER1 P34995 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
FFAR1 O14842 1/20 0.47
CD74 P04233 1/20 0.47
MIF P14174 1/20 0.47
ALDH1A1 P00352 1/20 0.46
APP P05067 1/20 0.46
GAA P10253 1/20 0.46
HCAR3 P49019 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
AXL P30530 1/20 0.45
ROCK2 O75116 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22467562 0.88 CDK8 (0.51) KMOCCNCCDK8FFAR1ALDH1A1
SCHEMBL1016124 0.81 CCNC (0.45) KMOCCNCCDK8FFAR1ROCK2
SCHEMBL6731024 0.81 MKNK1 (0.53) CCNCCDK8ALDH1A1APPGAA
SCHEMBL31733899 0.80 DDT (0.62) KMODDTPTGER1CYP3A4CYP2C9
SCHEMBL23873492 0.79 GRM4 (0.53) CCNCCDK8FFAR1
SCHEMBL2995452 0.79 NR1H4 (0.74) KMOAKR1C3AKR1C2NR1H4DDT
SCHEMBL31387853 0.79 GRM4 (0.53) CCNCCDK8FFAR1
SCHEMBL6252539 0.79 AKR1C3 (0.68) KMOAKR1C3AKR1C2NR1H4DDT
SCHEMBL27977721 0.79 TDP1 (0.48) KMOCCNCCDK8FFAR1ALDH1A1
SCHEMBL28372111 0.79 AKR1C3 (0.63) KMOAKR1C3AKR1C2NR1H4DDT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2980077-B1 PYRIDYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMA (US) 2020-05-06 EP disclosed
EP-2980077-A1 PYRIDYL DERIVATIVES AS CFTR MODULATORS Vertex Pharmaceuticals Incorporated (US) 2016-02-03 EP disclosed
EP-2615085-B1 Pyridyl derivatives as CFTR modulators VERTEX PHARMA (US) 2015-08-26 EP disclosed
EP-2271621-B1 PYRIDYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMA (US) 2013-11-20 EP disclosed
US-8524910-B2 Pyridyl derivatives as CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 US disclosed
EP-2615085-A1 Pyridyl derivatives as CFTR modulators Vertex Pharmaceuticals Incorporated (US) 2013-07-17 EP disclosed
US-20120270869-A1 PYRIDYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-25 US disclosed
US-8227615-B2 Pyridyl derivatives as CFTR modulators VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-07-24 US disclosed
EP-2271621-A1 PYRIDYL DERIVATIVES AS CFTR MODULATORS Vertex Pharmaceuticals Incorporated (US) 2011-01-12 EP disclosed
WO-2009123896-A1 PYRIDYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-08 WO disclosed
US-20090246137-A1 PYRIDYL DERIVATIVES AS CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090246137-A1 PYRIDYL DERIVATIVES AS CFTR MODULATORS CFTR, ABCC4, ABCB1 KMO 4371/4885AKR1C3 1739/4885AKR1C2 1963/4885
US-20120270869-A1 PYRIDYL DERIVATIVES AS CFTR MODULATORS CFTR, ABCC4, ABCB1 KMO 4371/4885AKR1C3 1739/4885AKR1C2 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.